Endocrine Challenges in Patients with Continuous-Flow Left Ventricular Assist Devices.

Gennaro Martucci, Federico Pappalardo, Harikesh Subramanian, Giulia Ingoglia, Elena Conoscenti, Antonio Arcadipane

Nutrients 2021 Mar 05

filter terms:

Heart failure (HF) remains a leading cause of morbidity, hospitalization, and mortality worldwide. Advancement of mechanical circulatory support technology has led to the use of continuous-flow left ventricular assist devices (LVADs), reducing hospitalizations, and improving quality of life and outcomes in advanced HF. Recent studies have highlighted how metabolic and endocrine dysfunction may be a consequence of, or associated with, HF, and may represent a novel (still neglected) therapeutic target in the treatment of HF. On the other hand, it is not clear whether LVAD support, may impact the outcome by also improving organ perfusion as well as improving the neuro-hormonal state of the patients, reducing the endocrine dysfunction. Moreover, endocrine function is likely a major determinant of human homeostasis, and is a key issue in the recovery from critical illness. Care of the endocrine function may contribute to improving cardiac contractility, immune function, as well as infection control, and rehabilitation during and after a LVAD placement. In this review, data on endocrine challenges in patients carrying an LVAD are gathered to highlight pathophysiological states relevant to this setting of patients, and to summarize the current therapeutic suggestions in the treatment of thyroid dysfunction, and vitamin D, erythropoietin and testosterone administration.

Citation

Gennaro Martucci, Federico Pappalardo, Harikesh Subramanian, Giulia Ingoglia, Elena Conoscenti, Antonio Arcadipane. Endocrine Challenges in Patients with Continuous-Flow Left Ventricular Assist Devices. Nutrients. 2021 Mar 05;13(3)